Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Invitation to conference call, October 21 at 13:30 pm CET

Studsvik AB presents its Interim Report for the third quarter 2021 and hereby invites media and analysts to a conference call held in English on Thursday, October 21 at 13:30 CET.Studsvik’s Interim Report for the third quarter 2021 will be distributed at approximately 12:00 CET, October 21. As of this time, the report will also be available at www.studsvik.com. The call will be held in English, starting 13:30 CET. Please call at least ten minutes prior to the start of the conference call to avoid delay. Event title is: Studsvik Q3 2021. Conference ID is: 1876858 Description

One third of people globally feel more positive about their homes in the past 12 months, new IKEA research reveals

Eighth annual IKEA Life at Home Report shows how homes have helped and hindered mental health and wellbeing around the world during the pandemic.Live streamed table talk today at 14:00 CET. Register here   · 40 percent of people who felt more positive toward their home in the last 12 months also saw their mental health improve · To achieve better balance at home, people say relaxation (53 percent) and alone time (38 percent) are the most important activities · Family relationships have taken centre stage during the pandemic, but one

Read original

Raisio plc: Raisio's converted shares

Raisio plc  Stock Exchange Release, 14 October 2021   RAISIO'S CONVERTED SHARES   The Board of Directors of Raisio plc has decided in its meeting held on 23 September 2021 to convert a total of 37,192 restricted shares (series K) into free shares (series V). The decision has been entered in the Trade Register today, on 14 October 2021. The additional lot of free shares in question is admitted to trading on the Nasdaq Helsinki Ltd as of 15 October 2021.   Since the beginning of 2021, a total of 484,734 restricted shares of the company have been converted into free shares.

BioStock: Positive phase I data for Ultimovacs

Biotech company Ultimovacs continues to strengthen the clinical evidence for its universal cancer vaccine UV1. On Wednesday morning the company could announce positive results from a phase I study of UV1 in combination with the checkpoint inhibitor pembrolizumab. The combination, which was tested in patients with metastatic malignant melanoma, showed the very encouraging survival rate of 80 per cent after 24 months.Read the full article at biostock.se:https://www.biostock.se/en/2021/10/positive-phase-i-data-for-ultimovacs/ This is a press release from BioStock - Connecting Innovation &

Last chance to tender shares in the recommended voluntary offer for all outstanding shares in Bank Norwegian ASA

NOT FOR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA AND JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE PRIOR APPROVAL. FOR MORE INFORMATION ABOUT NORDAX'S VOLUNTARY OFFER, PLEASE SEE NORDAX'S FORMAL OFFER ANNOUNCEMENT, AVAILABLE AT: WWW.COLLABORATE-TO-SCALE.COM.Reference is made to the offer document dated 5 August 2021 (the "Offer Document") for the recommended voluntary offer by Nordax Bank AB (publ) ("Nordax" or the "Offeror") to acquire all outstanding shares (the "Shares") in Bank Norwegian ASA ("Bank Norwegian" or the "Company")

Diaverum develops breakthrough AI model to deliver step-change in Vascular Access thrombosis prevention

Diaverum, a leading global renal care service provider, has developed an artificial intelligence model to support the company’s physicians and nurses predict with a high degree of accuracy, episodes of vascular access thrombosis among haemodialysed patients. Simulations using Diaverum’s historical patient data predicted an average of 75% of actual cases that were not detected by best-in-class clinical assessments and monitoring systems.Vascular Access (VA) thrombosis is a major factor of suffering and increased mortality for chronic haemodialysis patients, with incidence ranging between 0.

NORDEN PUBLISHES PROSPECTUS IN CONNECTION WITH ADMISSION TO TRADING AND OFFICIAL LISTING OF ITS USD 100,000,000 BONDS

ANNOUNCEMENT NO. 73 - 14 OCTOBER 2021 Not for release, publication or distribution, directly or indirectly, in any jurisdiction in which such release, publication or distribution would be unlawful Dampskibsselskabet NORDEN A/S has today published a listing prospectus prepared in connection with the admission to trading and official listing on Nasdaq Copenhagen A/S’ regulated market of its USD 100,000,000 senior unsecured bonds. The bonds were issued on 28 June 2021 and are senior unsecured bonds with a yearly coupon of 3-months LIBOR plus 4.75% with quarterly interest payments and

Invitation to Electrolux Professional AB Q3 2021 presentation

Electrolux Professional AB will publish the Q3 2021 interim report for the period July – September 2021, on Thursday, October 28, at 08:00 CETA telephone conference will be held at 09:00 CET with Alberto Zanata, CEO and Fabio Zarpellon, CFO presenting the result, followed by a Q&A session. The presentation will be available on https://www.electroluxprofessional.com/corporate/Please use the following dial-in details to participate in the telephone conference: Sweden: +46 8 566 427 04United Kingdom: +44 333 300 9269United States: +1 833 526 8382 The telephone conference and

Vitec Software Group AB Interim report January - September 2021

Summary of interim period, January–September 2021 · Net sales SEK 1,150 million (951), an increase of 21% · Recurring revenues SEK 975 million (796), an increase of 22% including 9% organic · EBITA was SEK 327 million (247), with an EBITA margin of 28% (26) · Operating profit was SEK 213 million (158), with an operating margin of 18% (17) · Earnings per share before dilution SEK 4.55 (3.51) · Cash flow from operating activities SEK 430 million (375) Summary of interim period, July–September 2021 · Net sales SEK 380 million (321), an increase of 19% · Recurring

Fiskars to publish its Interim Report for January-September 2021 on October 29, 2021

Fiskars Corporation Press release October 14, 2021 at 9:00 (EEST)     Fiskars to publish its Interim Report for January-September 2021 on October 29, 2021   Fiskars Corporation will publish its Interim Report for January-September 2021 on October 29, 2021 at approximately 8:30 a.m. (EEST). The report will be available on the company's website www.fiskarsgroup.com after publication.   Webcast A webcast on the third quarter results will be held on October 29, 2021 at 11:00. It will be held in English and can be followed at: https://fiskars.videosync.fi/2021-q3-

Metso Outotec wins order for Foresight™ semi-mobile primary gyratory crushing plant at Codelco’s Radomiro Tomic operation

Metso Outotec Corporation’s press release on October 14, 2021, at 09:00 a.m. EESTMetso Outotec has signed an agreement with Codelco in Chile to design and supply a Foresight™ semi-mobile primary gyratory (SMPG) crushing plant for Codelco’s Radomiro Tomic operation. The value of the order is not disclosed. It has been booked in Minerals’ Q3/2021 orders received. Equipped with a Superior™ MKIII 60-110 primary gyratory crusher, apron feeder discharge and dust collection, the Foresight™ SMPG meets the highest demands in productivity and sustainability. It is part of Metso Outotec’s in-pit

UNION therapeutics announces enrollment of first patient in the OSIRIS Phase 2a study of oral orismilast for the treatment of mild to severe hidradenitis suppurativa

· OSIRIS is an investigator-led, proof-of-concept Phase 2 study of orismilast for the treatment of mild to severe hidradenitis suppurativa (HS) · HS is a scarring inflammatory skin disease with significant unmet treatment need · Orismilast is a next generation PDE4 inhibitor with broad anti-inflammatory properties also in development for the treatment of psoriasis and atopic dermatitis Hellerup, Denmark, 14 October 2021 – UNION therapeutics A/S, a privately-held, multi-asset, clinical stage, pharmaceutical company focused on immunology and infectious diseases, today announced the

TOMRA: Invitation to Q3 2021 Presentation

TOMRA's third quarter 2021 results will be released Friday 22 October 2021. President & CEO Tove Andersen and CFO Espen Gundersen will present the results at 08:00 CEST (UTC+2). The presentation will be sent via live webcast. Questions to the speakers can be directed using the Q&A-tool embedded in the webcast and will be addressed towards the end of the presentation. A recorded version of the webcast will be available shortly after the webcast has concluded. Link to webcast will be available on www.tomra.com (Investor Relations section). All written materials including

Essity and McDonald’s are closing the loop for paper cups in Germany

Beverage, milkshake and ice cream cups will be re-used to make professional hygiene paper under Essity’s leading Tork brand.Hygiene and health company Essity and McDonald’s are writing circular history with a recycling project that turns used paper cups into a new resource. Starting in 2020, the project consisting of a team from Essity, logistics partner HAVI, and McDonald’s Deutschland LLC, has piloted different opportunities to give paper cup waste a new life. The pilot showed that Essity can successfully use the paper cups, after they have been shredded, as material for some of

New drilling campaign starts at Eurobattery Minerals Finnish battery mineral project

· The new drilling campaign, starting in mid-October 2021, will target the Hautalampi project resource increase · The campaign will cover the previously non-drilled gap area between the Hautalampi deposit and the north-eastern extension of the project known as the Mökkivaara deposits aiming to verify resources between these already established deposits.   · Previous drilling campaign in 2020 confirmed a resource increase of approximately 100% · With a target of approximately 5,000 meters of new drilling, the campaign will be finalized in early 2022 Stockholm, 14th October 2021.

Peab builds tenant-owner apartments for HSB in Uppsala

Peab has been commissioned to build 93 tenant-owner apartments in Librobäck in Uppsala Municipality. The customer is HSB Produktion i Uppsala HB and the contract is worth SEK 190 million.The apartments in the Brf Normann will be between 32 to 122 m2 with one to five rooms and a kitchen, and all will have access to an elevator and parking. In addition to the 93 tenant-owner apartments there will be an apartment for overnight stays and four premises on the ground floor. The facade will be plastered. “We’re proud to have been entrusted to build the final stage of the borough. As the Nordic

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00B635TG28 Issuer Name ENQUEST PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights; An acquisition or disposal of financial instruments 3. Details of person subject to the notification obligation Name Helikon Investments Limited City of registered office (if applicable) London Country of registered office (if applicable) United Kingdom 4. Details of the shareholder Name City of registered office

Embracer Group acquires mobile game developer Jufeng Studio and eight mobile titles

Embracer Group AB (”Embracer”), through its wholly owned subsidiary DECA Games, has acquired Gaea’s mobile studio Jufeng and its six titles. Through the acquisition DECA Games gains access to a talent base in China, providing a foundation for further growth in the Asia Pacific Region. DECA Games has also acquired two mobile titles, Hero Hunters and Killshot Bravo, from Hothead Games Inc. DECA Games’ internal studios in Europe will continue the live operations and development of these two titles. In the quarter July to September 2021, the eight acquired titles in total had approximately

ABGSC – Q3 2021 Interim Report

Highlights: · Strongest ever Q3 with revenues of NOK 561m (+55%) · YTD revenues of NOK 2,108m, up 104% from NOK 1,033m · YTD diluted EPS of NOK 1.02 (0.32) · Solid and diversified pipeline heading into Q4 and 2022 CEO comment: Despite normally being the seasonally slowest quarter, Q3 2021 turned out to be yet another record-breaking quarter with revenues of NOK 561m (+55%). Following the summer holidays, there has been a high level of activity as we continue to grow our business across markets, products and sectors. Although ECM continues to be the strongest revenue

Konecranes’ January-September 2021 interim report will be published on October 28, 2021

KONECRANES PLC PRESS RELEASE October 14, 2021 at 09:00 EEST Konecranes’ January-September 2021 interim report will be published on October 28, 2021 Konecranes will publish its January-September 2021 interim report on Thursday, October 28, 2021 at approximately 8:30 a.m. EEST. The report will be available on the company’s website at www.konecranes.com after publishing. A live international telephone conference for analysts, investors and media will be arranged on the publishing day at 10:30 a.m. EEST. The event will be held in English. The January-September 2021 interim report will

New Jobilla study: Successful recruiting has become harder in the past five years

·  40% of organizations can't name their most effective recruitment channels · 28% of respondents don't know how much money is spent on their recruitment campaigns. · Less than 20% of companies have been able to recruit more qualified candidatesTalent acquisition startup Jobilla  has conducted a recruitment study on the recruitment processes, resources, and channels companies utilize. 205 HR professionals from small companies to big corporations representing a wide mix of industries were interviewed and surveyed for the study. The study shows that most

Oblique Therapeutics is excited to present the recent progress on its anti-Thioredoxin mAb program at the annual meeting of Society for Immunotherapy of Cancer, Nov 10 – 14, Washington DC, USA.

Press release 14 October, 2021 Gothenburg, 14 October 2021 – Oblique Therapeutics, a biotech focused on new medicines for severe diseases with large unmet medical needs, will present the recent progress on its anti-Thioredoxin mAb program at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021, Nov 10 -14, Washington DC, USA.The poster titled ” Targeting the intersection of immunology and redox biology: therapeutic potential of an anti-Thioredoxin antibody ” will describe the identification of high affinity monoclonal antibodies against human Thioredoxin and in vitro and in

Kesko’s sales grew in September

Kesko Group's sales totalled €1,019.2 million in September 2021, representing an increase of 9.8% on the previous year. In comparable terms, sales grew by 9.0%.“Kesko’s sales continued to grow in September. Sales for the grocery trade division grew by 5.3%. Sales for the building and technical trade division grew by 16.4% in comparable terms. Sales for the building and technical trade division grew in all operating countries thanks to strong performance in B2B trade,” says Kesko’s President and CEO Mikko Helander. Sales for the grocery trade division totalled €507.9 million in September,

Nordhealth appoints new Chief Financial Officer, as current CFO transitions to CEO of Nordhealth’s veterinary business unit

Nordhealth AS (NORDH) announces the appointment of Mari Orttenvuori as the new Chief Financial Officer (CFO). Prior to joining Nordhealth, Ms. Orttenvuori has held the position of CFO at Enfo, a Nordic IT service company, CFO at M-Brain, a global competitive & market intelligence solutions company and VP of Finance at Oriola, a Nordic health and wellbeing company. The appointment is the result of a long-term plan to transition the current CFO of Nordhealth, Valter Pasanen, to the position of CEO of Nordhealth’s veterinary business unit. Both will assume their new roles on the 3rd of

There are no items matching the current filter
There are no more items matching the current filter
Back to top